CVS Will Pay $36.5 Million to Settle Insulin Fraud Claims With State AGs, DOJ
By Anvee Bhutani
CVS agreed to pay $36.5 million to resolve allegations that it fraudulently overbilled Medicaid for insulin prescriptions during a 10-year period.
The pharmacy retail giant reached an agreement to settle the claims brought by 36 attorneys general and the Justice Department, New York Attorney General Letitia James said Tuesday.
As part of the settlement, $25.1 million will be paid to Medicaid programs in participating states. New York will receive $2.3 million as part of the agreement
"From 2010 to 2020, CVS knowingly dispensed more insulin to customers than they needed while maintaining that they were reporting the correct amount of insulin in their prescriptions," James said.
CVS said it was pleased to have resolved the matter and noted that labeling changes, insulin dosing variability, and varying payor supply limits made "billing for these medications incredibly complex." Agreement on a settlement was first announced in December, the company said.
Write to Anvee Bhutani at anvee.bhutani@wsj.com
(END) Dow Jones Newswires
June 09, 2026 17:18 ET (21:18 GMT)
Copyright (c) 2026 Dow Jones & Company, Inc.The articles, information, and content displayed on this webpage may include materials prepared and provided by third parties. Such third-party content is offered for informational purposes only and is not endorsed, reviewed, or verified by Morningstar.
Morningstar makes no representations or warranties regarding the accuracy, completeness, timeliness, or reliability of any third-party content displayed on this site. The views and opinions expressed in third-party content are those of the respective authors and do not necessarily reflect the views of Morningstar, its affiliates, or employees.
Morningstar is not responsible for any errors, omissions, or delays in this content, nor for any actions taken in reliance thereon. Users are advised to exercise their own judgment and seek independent financial advice before making any decisions based on such content. The third-party providers of this content are not affiliated with Morningstar, and their inclusion on this site does not imply any form of partnership, agency, or endorsement.
Popular
3 Stocks to Sell and 3 Stocks to Buy for October
Undervalued by 15%, This Utilities Stock Could Be an Unexpected AI Winner
The Thrilling 37
The Smartest Moves for Bond Investors Today, and What to Do When You Have Too Many Investments
United States